Following the announcement that AstraZeneca (AZN) would not be accepting a sweetened takeover offer from Pfizer (PFE), AstraZeneca Chairman Leif Johansson said the company’s board would have recommended a bid if it had been GBP58.85 per share, which is at least 10% above Pfizer’s previous bid of GBP53.50 per share. JohanssonRead More
Post Tagged with: "AstraZeneca"
Panmure Gordon analysts downgraded AstraZeneca (AZN) to hold from a buy rating. Price target information was not available. AZN shares dropped more than 10% to $71.92 in early trading Monday. The stock has a 52-week range of $46.87 to $82.68. [ | | | | | | | | | | |Read More